KIYATEC to Present Data on Advanced Ex Vivo 3D Cell Culture Technology to Aid Cancer Patient Care and Drug Development at AACR 2019
GREENVILLE, SC. – March 28, 2019 – KIYATEC, Inc., today announced that it will be presenting research and exhibiting (booth# 2848) at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, GA, March 29-April 3.
Following is a list of poster presentations at AACR 2019.
- Predicting Patient Response to Immuno-Oncology Agents in Vitro Using 3D Culture
o Poster presentation 500/13, Session:PO.IMI01.05 – Imaging the Tumor Microenvironment, Section 20
o Sunday, March 31, 1:00 PM – 5:00 PM
- Ex Vivo Models of Glioblastoma: A Comparison of 3D Tissues and Patient-Derived Xenografts to Clinical Response
o Poster Presentation 53/25, Session PO.TB01.01 – 3D Models, Section 2
o Sunday, March 31, 1:00 PM – 5:00 PM
- Redefining Personalized Medicine by Drug Response Profiling of Patient-Derived Spheroids
o Poster Presentation 2240/29, Session PO.CL11.11 – Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 3, Section 18
o Monday, April 1, 1:00 PM – 5:00 PM
About KIYATEC, Inc.
KIYATEC is dedicated to accurately modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision making and drive drug development.
Our predictive clinical tests provide oncologists with patient-specific response profiles to current standard of care drugs prior to treatment selection.
Our predictive 3D models are being used by leading biopharmaceutical companies to increase the success of their preclinical and clinical drug development programs as they develop the cancer therapies of the future.
Contacts
MacDougall
Lauren Arnold, 781-235-3060
larnold@macbiocom.com